You are here:

fluticasone/formoterol (Flutiform)

Advice

following an abbreviated submission

fluticasone proprionate and formoterol fumarate metered dose inhaler (flutiform®)  is accepted for use in NHS Scotland.

Indication under review: in the regular treatment of asthma where the use of a combination product [an inhaled corticosteroid (ICS) and a long-acting β2 agonist (LABA)] is appropriate:
• for patients not adequately controlled on ICS and ‘as required’ inhaled short-acting β2 
      agonist or
• for patients already adequately controlled on both an ICS and a LABA.

Flutiform® should be used in patients for whom fluticasone and formoterol are appropriate choices of corticosteroid and long-acting beta-agonist, respectively, and for whom a metered dose inhaler is an appropriate delivery device. It has demonstrated clinical non-inferiority to another combination product containing a corticosteroid and long-acting beta2-agonist and may offer cost savings.
 

Drug Details

Drug Name: fluticasone/formoterol (Flutiform)
SMC Drug ID: 736/11
Manufacturer: Napp Pharmaceuticals Ltd
Indication: for the regular treatment of asthma where the use of a combination product [an inhaled corticosteroid (ICS) and a long-acting β2 agonist (LABA)] is appropriate: for patients not adequately controlled on ICS and ‘as required’ inhaled short-acting β2 / for patients already adequately controlled on both an ICS and a LABA.
BNF Category:
Sub Category: 3.1 Bronchodilators
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 8 October 2012

Back